+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Future of Epidermolysis Bullosa R&D Pipeline Drugs and Companies- Analysis of Global Epidermolysis Bullosa Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

  • ID: 4745220
  • Report
  • January 2019
  • Region: Global
  • 90 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • Abeona Therapeutics Inc
  • Anterogen Co Ltd
  • BridgeBio Inc
  • Fibrocell Science Inc
  • InMed Pharmaceuticals Inc
  • Mesoblast Ltd
  • MORE
The global demand for Epidermolysis Bullosa treatment options is emerging rapidly driven by consumption in major emerging markets. As more growth opportunities will turn up over the medium to long term future, a large number of companies are working on Epidermolysis Bullosa pipeline. Companies quickly adapting to the change and moving their products to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and inadequate financial support are holding some of the Epidermolysis Bullosa pipeline companies from advancing their products into Phase 3 or Phase 4.

Epidermolysis Bullosa Report Description

The H1- 2019 pipeline review report on Epidermolysis Bullosa pipeline is a comprehensive study on the candidates in development across different phases worldwide. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Epidermolysis Bullosa pipeline compounds.

The Epidermolysis Bullosa pipeline guide presents information on all active drugs currently being developed for Epidermolysis Bullosa. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Epidermolysis Bullosa pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Epidermolysis Bullosa drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Epidermolysis Bullosa product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Epidermolysis Bullosa pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

The publisher has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Epidermolysis Bullosa pipeline report includes
  • An overview of Epidermolysis Bullosa disease including symptoms, causes, diagnosis and available treatment options is provided.
  • Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
  • Phase wise count of pipeline compounds
  • Company wise list of pipeline compounds
  • Mechanism of Action wise pipeline compounds
For each pipeline product, the following details are provided
  • Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)
  • Current status of development
  • Drug overview
  • Mechanism of Action
  • Pre-clinical and Clinical Trials
Reasons to Buy
  • The report is designed to help industry executives promote the success and continued growth of their organizations
  • Get clear understanding of the entire Epidermolysis Bullosa pipeline, with details on active projects
  • Stay ahead of the competition through comprehensive knowledge of Epidermolysis Bullosa pipeline progress
  • Get in detail information of each product with updated information on each project along with key milestones
  • Gain clear insights into the market through in-depth strategic analysis review
  • Know the list of companies participating in global Epidermolysis Bullosa pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data
  • Get trial information for each pipeline product under development
  • Understand the pipeline structure in terms of mechanism of Action, phase and company
The report will be delivered in 2 working days.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Abeona Therapeutics Inc
  • Anterogen Co Ltd
  • BridgeBio Inc
  • Fibrocell Science Inc
  • InMed Pharmaceuticals Inc
  • Mesoblast Ltd
  • MORE
1.1 List of Tables
1.2 List of Figures

2. Global Epidermolysis Bullosa Pipeline Overview
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Report Guide and Research Methodology

3. Executive Summary
3.1 Epidermolysis Bullosa Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
3.3 Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
3.4 Companies involved in Epidermolysis Bullosa pipeline, H1- 2019
3.5 Mechanism of Action wise Epidermolysis Bullosa Pipeline Candidates

4. Abeona Therapeutics Inc Epidermolysis Bullosa Pipeline Details
4.1 Abeona Therapeutics Inc Business Profile
4.2 Abeona Therapeutics Inc Epidermolysis Bullosa Drug Details
4.2.1 Drug Snapshot
4.2.1.1 Originator
4.2.1.2 Collaborator/Co-Developer
4.2.1.3 Route of Administration
4.2.1.4 Orphan Drug/Fast Track/Special Designation
4.2.1.5 Area
4.2.1.6 Type of Molecular Entity
4.3 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments

5. Aegle Therapeutics Corp Epidermolysis Bullosa Pipeline Details
5.1 Aegle Therapeutics Corp Business Profile
5.2 Aegle Therapeutics Corp Epidermolysis Bullosa Drug Details
5.2.1 Drug Snapshot
5.2.1.1 Originator
5.2.1.2 Collaborator/Co-Developer
5.2.1.3 Route of Administration
5.2.1.4 Orphan Drug/Fast Track/Special Designation
5.2.1.5 Area
5.2.1.6 Type of Molecular Entity
5.3 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments

6. Amryt Pharma plc Epidermolysis Bullosa Pipeline Details
6.1 Amryt Pharma plc Business Profile
6.2 Amryt Pharma plc Epidermolysis Bullosa Drug Details
6.2.1 Drug Snapshot
6.2.1.1 Originator
6.2.1.2 Collaborator/Co-Developer
6.2.1.3 Route of Administration
6.2.1.4 Orphan Drug/Fast Track/Special Designation
6.2.1.5 Area
6.2.1.6 Type of Molecular Entity
6.3 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments

7. Anterogen Co Ltd Epidermolysis Bullosa Pipeline Details
7.1 Anterogen Co Ltd Business Profile
7.2 Anterogen Co Ltd Epidermolysis Bullosa Drug Details
7.2.1 Drug Snapshot
7.2.1.1 Originator
7.2.1.2 Collaborator/Co-Developer
7.2.1.3 Route of Administration
7.2.1.4 Orphan Drug/Fast Track/Special Designation
7.2.1.5 Area
7.2.1.6 Type of Molecular Entity
7.3 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments

8. Azitra Inc Epidermolysis Bullosa Pipeline Details
8.1 Azitra Inc Business Profile
8.2 Azitra Inc Epidermolysis Bullosa Drug Details
8.2.1 Drug Snapshot
8.2.1.1 Originator
8.2.1.2 Collaborator/Co-Developer
8.2.1.3 Route of Administration
8.2.1.4 Orphan Drug/Fast Track/Special Designation
8.2.1.5 Area
8.2.1.6 Type of Molecular Entity
8.3 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments

9. Berg LLC Epidermolysis Bullosa Pipeline Details
9.1 Berg LLC Business Profile
9.2 Berg LLC Epidermolysis Bullosa Drug Details
9.2.1 Drug Snapshot
9.2.1.1 Originator
9.2.1.2 Collaborator/Co-Developer
9.2.1.3 Route of Administration
9.2.1.4 Orphan Drug/Fast Track/Special Designation
9.2.1.5 Area
9.2.1.6 Type of Molecular Entity
9.3 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments

10. BridgeBio Inc Epidermolysis Bullosa Pipeline Details
10.1 BridgeBio Inc Business Profile
10.2 BridgeBio Inc Epidermolysis Bullosa Drug Details
10.2.1 Drug Snapshot
10.2.1.1 Originator
10.2.1.2 Collaborator/Co-Developer
10.2.1.3 Route of Administration
10.2.1.4 Orphan Drug/Fast Track/Special Designation
10.2.1.5 Area
10.2.1.6 Type of Molecular Entity
10.3 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments

11. Constant Pharmaceuticals LLC Epidermolysis Bullosa Pipeline Details
11.1 Constant Pharmaceuticals LLC Business Profile
11.2 Constant Pharmaceuticals LLC Epidermolysis Bullosa Drug Details
11.2.1 Drug Snapshot
11.2.1.1 Originator
11.2.1.2 Collaborator/Co-Developer
11.2.1.3 Route of Administration
11.2.1.4 Orphan Drug/Fast Track/Special Designation
11.2.1.5 Area
11.2.1.6 Type of Molecular Entity
11.3 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments

12. CSL Ltd Epidermolysis Bullosa Pipeline Details
12.1 CSL Ltd Business Profile
12.2 CSL Ltd Epidermolysis Bullosa Drug Details
12.2.1 Drug Snapshot
12.2.1.1 Originator
12.2.1.2 Collaborator/Co-Developer
12.2.1.3 Route of Administration
12.2.1.4 Orphan Drug/Fast Track/Special Designation
12.2.1.5 Area
12.2.1.6 Type of Molecular Entity
12.3 Current Status
12.4 Drug Overview
12.5 Drug Mechanism of Action
12.6 Clinical/Pre-clinical Trial Details
12.7 Latest Drug Developments

13. Ember Therapeutics Inc Epidermolysis Bullosa Pipeline Details
13.1 Ember Therapeutics Inc Business Profile
13.2 Ember Therapeutics Inc Epidermolysis Bullosa Drug Details
13.2.1 Drug Snapshot
13.2.1.1 Originator
13.2.1.2 Collaborator/Co-Developer
13.2.1.3 Route of Administration
13.2.1.4 Orphan Drug/Fast Track/Special Designation
13.2.1.5 Area
13.2.1.6 Type of Molecular Entity
13.3 Current Status
13.4 Drug Overview
13.5 Drug Mechanism of Action
13.6 Clinical/Pre-clinical Trial Details
13.7 Latest Drug Developments

14. Fibrocell Science Inc Epidermolysis Bullosa Pipeline Details
14.1 Fibrocell Science Inc Business Profile
14.2 Fibrocell Science Inc Epidermolysis Bullosa Drug Details
14.2.1 Drug Snapshot
14.2.1.1 Originator
14.2.1.2 Collaborator/Co-Developer
14.2.1.3 Route of Administration
14.2.1.4 Orphan Drug/Fast Track/Special Designation
14.2.1.5 Area
14.2.1.6 Type of Molecular Entity
14.3 Current Status
14.4 Drug Overview
14.5 Drug Mechanism of Action
14.6 Clinical/Pre-clinical Trial Details
14.7 Latest Drug Developments

15. GlaxoSmithKline Plc Epidermolysis Bullosa Pipeline Details
15.1 GlaxoSmithKline Plc Business Profile
15.2 GlaxoSmithKline Plc Epidermolysis Bullosa Drug Details
15.2.1 Drug Snapshot
15.2.1.1 Originator
15.2.1.2 Collaborator/Co-Developer
15.2.1.3 Route of Administration
15.2.1.4 Orphan Drug/Fast Track/Special Designation
15.2.1.5 Area
15.2.1.6 Type of Molecular Entity
15.3 Current Status
15.4 Drug Overview
15.5 Drug Mechanism of Action
15.6 Clinical/Pre-clinical Trial Details
15.7 Latest Drug Developments

16. Holostem Terapie Avanzate Srl Epidermolysis Bullosa Pipeline Details
16.1 Holostem Terapie Avanzate Srl Business Profile
16.2 Holostem Terapie Avanzate Srl Epidermolysis Bullosa Drug Details
16.2.1 Drug Snapshot
16.2.1.1 Originator
16.2.1.2 Collaborator/Co-Developer
16.2.1.3 Route of Administration
16.2.1.4 Orphan Drug/Fast Track/Special Designation
16.2.1.5 Area
16.2.1.6 Type of Molecular Entity
16.3 Current Status
16.4 Drug Overview
16.5 Drug Mechanism of Action
16.6 Clinical/Pre-clinical Trial Details
16.7 Latest Drug Developments

17. Immusoft Corp Epidermolysis Bullosa Pipeline Details
17.1 Immusoft Corp Business Profile
17.2 Immusoft Corp Epidermolysis Bullosa Drug Details
17.2.1 Drug Snapshot
17.2.1.1 Originator
17.2.1.2 Collaborator/Co-Developer
17.2.1.3 Route of Administration
17.2.1.4 Orphan Drug/Fast Track/Special Designation
17.2.1.5 Area
17.2.1.6 Type of Molecular Entity
17.3 Current Status
17.4 Drug Overview
17.5 Drug Mechanism of Action
17.6 Clinical/Pre-clinical Trial Details
17.7 Latest Drug Developments

18. InMed Pharmaceuticals Inc Epidermolysis Bullosa Pipeline Details
18.1 InMed Pharmaceuticals Inc Business Profile
18.2 InMed Pharmaceuticals Inc Epidermolysis Bullosa Drug Details
18.2.1 Drug Snapshot
18.2.1.1 Originator
18.2.1.2 Collaborator/Co-Developer
18.2.1.3 Route of Administration
18.2.1.4 Orphan Drug/Fast Track/Special Designation
18.2.1.5 Area
18.2.1.6 Type of Molecular Entity
18.3 Current Status
18.4 Drug Overview
18.5 Drug Mechanism of Action
18.6 Clinical/Pre-clinical Trial Details
18.7 Latest Drug Developments

19. Krystal Biotech Inc Epidermolysis Bullosa Pipeline Details
19.1 Krystal Biotech Inc Business Profile
19.2 Krystal Biotech Inc Epidermolysis Bullosa Drug Details
19.2.1 Drug Snapshot
19.2.1.1 Originator
19.2.1.2 Collaborator/Co-Developer
19.2.1.3 Route of Administration
19.2.1.4 Orphan Drug/Fast Track/Special Designation
19.2.1.5 Area
19.2.1.6 Type of Molecular Entity
19.3 Current Status
19.4 Drug Overview
19.5 Drug Mechanism of Action
19.6 Clinical/Pre-clinical Trial Details
19.7 Latest Drug Developments

20. Life Sciences Institute Inc Epidermolysis Bullosa Pipeline Details
20.1 Life Sciences Institute Inc Business Profile
20.2 Life Sciences Institute Inc Epidermolysis Bullosa Drug Details
20.2.1 Drug Snapshot
20.2.1.1 Originator
20.2.1.2 Collaborator/Co-Developer
20.2.1.3 Route of Administration
20.2.1.4 Orphan Drug/Fast Track/Special Designation
20.2.1.5 Area
20.2.1.6 Type of Molecular Entity
20.3 Current Status
20.4 Drug Overview
20.5 Drug Mechanism of Action
20.6 Clinical/Pre-clinical Trial Details
20.7 Latest Drug Developments

21. MallInckrodt Plc Epidermolysis Bullosa Pipeline Details
21.1 MallInckrodt Plc Business Profile
21.2 MallInckrodt Plc Epidermolysis Bullosa Drug Details
21.2.1 Drug Snapshot
21.2.1.1 Originator
21.2.1.2 Collaborator/Co-Developer
21.2.1.3 Route of Administration
21.2.1.4 Orphan Drug/Fast Track/Special Designation
21.2.1.5 Area
21.2.1.6 Type of Molecular Entity
21.3 Current Status
21.4 Drug Overview
21.5 Drug Mechanism of Action
21.6 Clinical/Pre-clinical Trial Details
21.7 Latest Drug Developments

22. Mesoblast Ltd Epidermolysis Bullosa Pipeline Details
22.1 Mesoblast Ltd Business Profile
22.2 Mesoblast Ltd Epidermolysis Bullosa Drug Details
22.2.1 Drug Snapshot
22.2.1.1 Originator
22.2.1.2 Collaborator/Co-Developer
22.2.1.3 Route of Administration
22.2.1.4 Orphan Drug/Fast Track/Special Designation
22.2.1.5 Area
22.2.1.6 Type of Molecular Entity
22.3 Current Status
22.4 Drug Overview
22.5 Drug Mechanism of Action
22.6 Clinical/Pre-clinical Trial Details
22.7 Latest Drug Developments

23. Palvella Therapeutics LLC Epidermolysis Bullosa Pipeline Details
23.1 Palvella Therapeutics LLC Business Profile
23.2 Palvella Therapeutics LLC Epidermolysis Bullosa Drug Details
23.2.1 Drug Snapshot
23.2.1.1 Originator
23.2.1.2 Collaborator/Co-Developer
23.2.1.3 Route of Administration
23.2.1.4 Orphan Drug/Fast Track/Special Designation
23.2.1.5 Area
23.2.1.6 Type of Molecular Entity
23.3 Current Status
23.4 Drug Overview
23.5 Drug Mechanism of Action
23.6 Clinical/Pre-clinical Trial Details
23.7 Latest Drug Developments

24. Phoenix Tissue Repair Inc Epidermolysis Bullosa Pipeline Details
24.1 Phoenix Tissue Repair Inc Business Profile
24.2 Phoenix Tissue Repair Inc Epidermolysis Bullosa Drug Details
24.2.1 Drug Snapshot
24.2.1.1 Originator
24.2.1.2 Collaborator/Co-Developer
24.2.1.3 Route of Administration
24.2.1.4 Orphan Drug/Fast Track/Special Designation
24.2.1.5 Area
24.2.1.6 Type of Molecular Entity
24.3 Current Status
24.4 Drug Overview
24.5 Drug Mechanism of Action
24.6 Clinical/Pre-clinical Trial Details
24.7 Latest Drug Developments

25. ProQR Therapeutics NV Epidermolysis Bullosa Pipeline Details
25.1 ProQR Therapeutics NV Business Profile
25.2 ProQR Therapeutics NV Epidermolysis Bullosa Drug Details
25.2.1 Drug Snapshot
25.2.1.1 Originator
25.2.1.2 Collaborator/Co-Developer
25.2.1.3 Route of Administration
25.2.1.4 Orphan Drug/Fast Track/Special Designation
25.2.1.5 Area
25.2.1.6 Type of Molecular Entity
25.3 Current Status
25.4 Drug Overview
25.5 Drug Mechanism of Action
25.6 Clinical/Pre-clinical Trial Details
25.7 Latest Drug Developments

26. RegeneRx Biopharmaceuticals Inc Epidermolysis Bullosa Pipeline Details
26.1 RegeneRx Biopharmaceuticals Inc Business Profile
26.2 RegeneRx Biopharmaceuticals Inc Epidermolysis Bullosa Drug Details
26.2.1 Drug Snapshot
26.2.1.1 Originator
26.2.1.2 Collaborator/Co-Developer
26.2.1.3 Route of Administration
26.2.1.4 Orphan Drug/Fast Track/Special Designation
26.2.1.5 Area
26.2.1.6 Type of Molecular Entity
26.3 Current Status
26.4 Drug Overview
26.5 Drug Mechanism of Action
26.6 Clinical/Pre-clinical Trial Details
26.7 Latest Drug Developments

27. RHEACELL GmbH & Co KG Epidermolysis Bullosa Pipeline Details
27.1 RHEACELL GmbH & Co KG Business Profile
27.2 RHEACELL GmbH & Co KG Epidermolysis Bullosa Drug Details
27.2.1 Drug Snapshot
27.2.1.1 Originator
27.2.1.2 Collaborator/Co-Developer
27.2.1.3 Route of Administration
27.2.1.4 Orphan Drug/Fast Track/Special Designation
27.2.1.5 Area
27.2.1.6 Type of Molecular Entity
27.3 Current Status
27.4 Drug Overview
27.5 Drug Mechanism of Action
27.6 Clinical/Pre-clinical Trial Details
27.7 Latest Drug Developments

28. Shionogi & Co Ltd Epidermolysis Bullosa Pipeline Details
28.1 Shionogi & Co Ltd Business Profile
28.2 Shionogi & Co Ltd Epidermolysis Bullosa Drug Details
28.2.1 Drug Snapshot
28.2.1.1 Originator
28.2.1.2 Collaborator/Co-Developer
28.2.1.3 Route of Administration
28.2.1.4 Orphan Drug/Fast Track/Special Designation
28.2.1.5 Area
28.2.1.6 Type of Molecular Entity
28.3 Current Status
28.4 Drug Overview
28.5 Drug Mechanism of Action
28.6 Clinical/Pre-clinical Trial Details
28.7 Latest Drug Developments

29. TWi Biotechnology Inc Epidermolysis Bullosa Pipeline Details
29.1 TWi Biotechnology Inc Business Profile
29.2 TWi Biotechnology Inc Epidermolysis Bullosa Drug Details
29.2.1 Drug Snapshot
29.2.1.1 Originator
29.2.1.2 Collaborator/Co-Developer
29.2.1.3 Route of Administration
29.2.1.4 Orphan Drug/Fast Track/Special Designation
29.2.1.5 Area
29.2.1.6 Type of Molecular Entity
29.3 Current Status
29.4 Drug Overview
29.5 Drug Mechanism of Action
29.6 Clinical/Pre-clinical Trial Details
29.7 Latest Drug Developments

20. Latest Epidermolysis Bullosa Drug Pipeline Developments, 2019

21. Appendix
21.1 About Us
21.2 Sources and Methodology
21.3 Contact Information
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Abeona Therapeutics Inc
  • Aegle Therapeutics Corp
  • Amryt Pharma plc
  • Anterogen Co Ltd
  • Azitra Inc
  • Berg LLC
  • BridgeBio Inc
  • Constant Pharmaceuticals LLC
  • CSL Ltd
  • Ember Therapeutics Inc
  • Fibrocell Science Inc
  • GlaxoSmithKline Plc
  • Holostem Terapie Avanzate Srl
  • Immusoft Corp
  • InMed Pharmaceuticals Inc
  • Krystal Biotech Inc
  • Life Sciences Institute Inc
  • MallInckrodt Plc
  • Mesoblast Ltd
  • Palvella Therapeutics LLC
  • Phoenix Tissue Repair Inc
  • ProQR Therapeutics NV
  • RegeneRx Biopharmaceuticals Inc
  • RHEACELL GmbH & Co KG
  • Shionogi & Co Ltd
  • TWi Biotechnology Inc
Note: Product cover images may vary from those shown
Adroll
adroll